The U.S. Food and Drug Administration recently granted clearance for a vibration belt known as Osteoboost, a prescription device that aims to reduce bone loss in post-menopausal women.
Bone Health Technologies Appoints Laura Yecies as Chief Executive Officer
April 07, 2021 12:11 ET | Source: Bone Health Technologies Bone Health Technologies San Francisco, California
SAN FRANCISCO, Calif., April 07, 2021 (GLOBE NEWSWIRE) Bone Health Technologies, a leading innovator of progressive new therapies for improving bone health, today announced the appointment of tech veteran Laura Yecies as Chief Executive Officer.
Yecies has successfully led multiple startups and top technology brands over her career of more than 20 years in Silicon Valley. A Harvard MBA with an MSFS from Georgetown, she is an experienced CEO, marketing executive and strategist with a proven ability to develop and market award-winning products, build teams, scale businesses, as well as profitably exit. Yecies was previously a Board Member of Bone Health Technologies, and will focus on expanding the team to execute strategy and accelerate growth.
Women Who Lead: Closing the medical research gap between men and women - San Francisco Business Times bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Bone Health Technologies introduces the OsteoBoost Vibration Belt, designed to help treat osteopenia and prevent osteoarthritis. It has been granted “Breakthrough Device” designation by the US Food & Drug Administration.
OsteoBoost uses proprietary vibration technology designed to deliver gentle mechanical stimulation to the hips and spine at a precise, individually calibrated frequency, encouraging the body to reduce bone resorption and potentially create new bone. This localized vibration therapy’s effect is to stop the progression of bone loss and prevent the onset of osteoporosis.
An initial study suggests that one 30-minute treatment with OsteoBoost helps reduce bone loss activity in all study participants, providing an average decrease of 14%, a reduction on par with bisphosphonate drugs.